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Abstract 34 
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited 35 
treatment options.  Many compounds have shown efficacy in pre-clinical models of this condition, 36 
but only Pirfenidone and Nintedanib have been approved for clinical use. It is widely accepted that 37 
the current animal models of IPF need to be improved and in this review we have critically evaluated 38 
the current state of play of preclinical models of IPF and discuss the challenges facing this field. The 39 
popular model of a single I.T. administration of bleomycin could be adapted to provide a more 40 
progressive fibrosis as is thought to occur in humans. Furthermore, currently the majority of new 41 
drugs are investigated in preclinical models of IPF are dosed using a prophylactic dosing regimen, 42 
whereas patients are almost always treated after the fibrosis is well established. Using a therapeutic 43 
dosing regimen in preclinical models would be a better way to establish potential efficacy of new 44 
drugs. The most popular endpoints examined in pre-clinical models of IPF are histological scoring 45 
and lung collagen content. However in IPF patients imaging and lung function tests are more 46 
commonly used as end points. We propose that examining more clinically relevant endpoints in pre-47 
clinical models could also provide give a better indication of a compound’s potential efficacy on 48 
endpoints measured in patients. 49 
Keywords 50 
Animal Models; IPF; Pre-clinical 51 
 52 
Introduction 53 
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterised by scarring 54 
of the lung tissue causing impaired gas exchange leading to symptoms such as dyspnoea, dry cough, 55 
and general fatigue. IPF is more prevalent in males than females and risk factors include increased 56 
age, a history of smoking and working in environments with poor air quality, such as mining [1-4]. 57 
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There also appears to be a genetic component of IPF with variations of genes such as MUC5B and 58 
TOLLIP conferring a greater risk of developing IPF [3]. 59 
 Despite the relatively recent approval of Pirfenidone and Nintedanib (approved in Europe in 2011 60 
and 2015 respectively) which have both been shown to slow the progression of IPF in clinical trials 61 
[5,6] the prognosis of IPF is still very poor with approximately 50% of patients dying within 2-5 years 62 
of diagnosis [1, 2, 4]. Part of the reason for this poor prognosis is that the symptoms of IPF often 63 
don’t present until the disease is at an advanced stage [2, 7], and also delays in diagnosis can occur 64 
as the symptoms of IPF are shared with several other respiratory disorders, and either a high 65 
resolution CT scan or lung biopsy are required to definitively diagnose IPF [8]. The fact that IPF can 66 
remain undetected for so long means that pharmacological intervention is often not introduced until 67 
the disease is already well established. In addition, the pathogenesis of IPF is not fully understood. 68 
However, it is currently thought that repeated lung injury or infection leads to an aberrant wound 69 
healing process which causes massive extra cellular matrix deposition and the scarring of lung tissue 70 
that is characteristic of IPF [9].  71 
The incomplete understanding of the disease and lack of safe and effective treatment makes IPF a 72 
disease with considerable unmet need requiring novel approaches to treatment. To this end there 73 
has been a considerable amount of research in this area and a wide variety of different in vivo 74 
models have been used to investigate IPF over many years, but there remains no consensus on 75 
preclinical tests best used to model IPF and to have predictive value of clinical efficacy. Many 76 
different research groups have published work attempting to model IPF use different species, 77 
different fibrotic insults and different dosing routes and regimes to illicit a fibrotic response in the 78 
lungs of the animals. However, there is little consistency between laboratories regarding optimal 79 
protocols for these preclinical models. 80 
The aim of this review is therefore to detail and compare the different in vivo models used to 81 
investigate IPF, to review the effects of different pharmacological classes of drugs evaluated in these 82 
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models and to critically discuss how these effects have translated into treatment for patients with 83 
IPF. Furthermore, we have suggested potential ways for improving the current preclinical models in 84 
IPF research. 85 
Overview of current pre-clinical models of pulmonary fibrosis 86 
Pulmonary fibrosis like features can be induced in experimental animals by very diverse agents, and 87 
these different agents can be administered via many different routes and using distinctive dosing 88 
regimens. We have summarised these different approaches in Table 1. Since the early 1970’s when 89 
bleomycin was recognised as a drug able to induce pulmonary fibrosis as an unwanted effect in 90 
some patients, bleomycin has been the most widely used agent to induce pulmonary fibrosis in 91 
animals [10-12]. Bleomycin induces pulmonary fibrosis by production of DNA-cleaving superoxide 92 
and hydroxide free radicals which cause single and double stranded DNA breaks [13]. This damage 93 
preferentially occurs in the lungs because of low levels of bleomycin hydrolase, a bleomycin 94 
inactivating enzyme [14]. Bleomycin has been used in a variety of different species via a number of 95 
administration routes and regimes. Probably the most popular and best characterised animal model 96 
involves a single I.T. dose of bleomycin in rats or mice. This dosing regime leads to a neutrophil 97 
driven inflammatory response which lasts approximately 7-10 days, which then transforms into a 98 
fibrotic response from approximately Day 14 [15,16]. Terminal investigations are typically carried out 99 
on Day 21 or 28 after the initial bleomycin dose. This model has provided valuable insight into the 100 
process of pulmonary fibrosis, for example elucidation of the importance of the role of TGF-β in the 101 
development of IPF [17]. Furthermore, this model was used in the pre-clinical development of 102 
Nintedanib [18]. However, this bleomycin model does have several limitations with the most 103 
concerning being the fact that the fibrosis has been shown to spontaneously resolve beyond 28 days 104 
[15,19]. Since fibrosis does not resolve in most patients with pulmonary fibrosis, the use of this 105 
model is limited to the evaluation of the efficacy of potential anti-fibrotic compounds 106 
prophylactically. Many other bleomycin dose routes and regimes have been used to try and better 107 
model the progressive nature of IPF with repeated lower doses of bleomycin delivered both locally 108 
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to the lungs [20,21] or systemically [22,23]. For example, with a lower repeated I.T. dose of 109 
bleomycin, Peng et al [21] were able to show fibrotic like changes in the lungs up to 24 weeks after 110 
the initial bleomycin dose. However, the length of time that this model takes to develop and the 111 
significant mortality observed with this dosing regimen are limitations of this dosing regimen [21].  112 
As well as bleomycin several other fibrotic agents have been used with varying degrees of success. 113 
Fluorescein isothiocyanate (FITC) has been shown to cause fibrosis like changes over a similar time 114 
scale to bleomycin.  FITC is a fluorescent molecule with the advantage that molecular deposition in 115 
the lung can be easily visualised [2, 24, 25]. The disadvantages of this model are that certain 116 
histopathological features, such as fibroblast foci, are not observed, and there is a large amount of 117 
variation in the fibrotic response generated by different batches of FITC [2]. 118 
 Administration of silica or asbestos to the lungs has also been shown to illicit persistent fibrosis like 119 
changes [18, 26-28]. However, as with FITC, there are histopathological features that are missing 120 
with respect to the histopathological features seen in patients with IPF. The pulmonary conditions 121 
that develops following exposure to silica or asbestos are more akin to the human disease of silicosis 122 
or asbestosis respectively rather than pulmonary fibrosis. 123 
Systemic delivery of paraquat also produces fibrosis like changes in the lungs of animals [29-31]. 124 
However, paraquat is a broad spectrum herbicide that has been shown to cause necrosis in organs 125 
other than the lungs (such as kidney and liver) which can cause significant mortality and thus 126 
provides considerable challenges as a model associated with fibrosis-specific changes to the lungs 127 
[31]. 128 
Certain non-chemical in vivo approaches can induce pulmonary fibrosis. An exposure of the thorax of 129 
animals to radiation has been shown to result in persistent fibrosis like changes in the lungs [32,33]. 130 
However, as the fibrosis takes a long time to develop and the cost of the irradiating equipment can 131 
be high, this model is very expensive to run. The pulmonary response to radiation exposure also 132 
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lacks some of the histopathological features seen in patients with IPF such as complex fibroblast foci 133 
[1,2]. 134 
Intra-tracheal delivery of transgenes using viral vectors has shown some success, with delivery of 135 
genes for factors such as TGF-β1 and IL-1β eliciting fibrotic responses in the lungs of animals [34-36]. 136 
Although delivery of these transgenes leads to a progressive and persistent fibrosis (up to 9 weeks in 137 
certain studies [34,35], the downside of such models can be that the animals may have an immune 138 
response to the viral vector, and the expression of the transgenes is much higher than 139 
physiologically possible. Therefore, the pathways through which the transgene products work will be 140 
massively over activated which question the relevance of this approach as a model to test potential 141 
novel anti-fibrotic compounds. 142 
Another animal model of pulmonary fibrosis that has been utilised is a humanized mouse model of 143 
IPF, where cells from human patients of IPF are injected into SCID mice. Infusion of human 144 
fibroblasts has been shown to lead to increases in fibrosis seen histologically and upregulation of 145 
pro-fibrotic genes such as TGF-β1 and surfactant proteins at 63 days post infusion [37]. However, the 146 
main issue with this model is the availability of cells from human patients with IPF, and also the 147 
length of time to generate fibrosis in this model. 148 
As well as many different agents, and dosing regimens, many different species have been used to 149 
model IPF. The most common are mice and rats due to the ease of handling, availability of reagents, 150 
their well characterised immune systems, and the possibility of utilising transgenic models in mice 151 
[38,39]. There are however, considerable differences in the structure and physiology of rat and 152 
mouse lungs compared to human lungs [40-42]. Furthermore, one particular aspect of human IPF 153 
that is impossible to model in rats and mice is cough. Although there is some controversy over 154 
whether mice and rats have the ability to cough it is clear that at best they have a greatly reduced 155 
sensitivity to common tussive agents such as citric acid or capsaicin that induce cough in patients 156 
with IPF [43,44] .  In contrast, guinea pigs have a well characterised and generally robust cough 157 
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response and so are the animal of choice for studying cough [43,44]. As chronic cough is a major 158 
symptom of IPF affecting over 80% of patients [45,46], some groups have used induced pulmonary 159 
fibrosis in guinea pigs in order to be able to investigate the cough caused by pulmonary fibrosis.  160 
Another feature of rats and mice that may be a limiting factor in their usefulness for the study of 161 
pulmonary fibrosis is their small size. Using larger animals to model pulmonary fibrosis can have a 162 
number of advantages. For example the use of the sheep [16] has permitted the use of a fibre-optic 163 
bronchoscope to deliver bleomycin to a specific segment of lung. This specific delivery of bleomycin 164 
means that the overall burden on the animal is much lower as the remaining lung is easily able to 165 
compensate for the damage in the segment administered the bleomycin. Due to this compensation 166 
of the rest of the lung a higher relative dose of bleomycin can be used in the target segment to 167 
induce a more severe fibrosis that may be more akin to what is seen in advanced pulmonary fibrosis 168 
patients, a feature of the clinical disease that is difficult to model in animals where the whole lung is 169 
exposed to the fibrotic agent leading to significant levels of tissue damage raising a large number of 170 
animal welfare issues. 171 
Table 1: An overview of in vivo animal models used to study IPF 
Species Fibrotic Agent Route and regime Ref 
Mouse Bleomycin Single I.T. dose 18, 21,47-
50 
Mouse Bleomycin Repeat I.T. dose 20,21 
Mouse Bleomycin Single I.N. dose 51 
Mouse Bleomycin Repeat I.N. dose 52,53 
Mouse Bleomycin Repeat I.P. dose 22,54 
Mouse Bleomycin Repeat O.A. dose 53,55 
Mouse Bleomycin Repeat I.V. dose 23 
Mouse Bleomycin Single I.V. dose 56 
Mouse Bleomycin S.C. osmotic mini pump 57,58 
Rat Bleomycin Single I.T. dose 18,59-62 
Rat Bleomycin Repeat I.N. dose 53 
Rat Bleomycin Repeat O.A. dose 53 
Sheep Bleomycin Segmental lung instillation  63 
Dog Bleomycin Repeat I.V. dose 10 
Guinea Pig Bleomycin Single I.T. dose 64 
Mouse Fluorescein isothiocyanate 
(FITC)  
Single I.T. dose 24,25 
Mouse Silica Single I.T. dose 18 
Mouse Silica Repeat O.A. dose 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
Rat Silica Inhaled repeat dose 28 
Mouse Radiation Single thorax exposure 32,33 
Mouse Viral vector delivery of TGF-
β1 transgene 
Single I.T. dose 36 
Rat Viral vector delivery of IL-1β 
transgene  
Single I.T. dose 34 
Rat  Viral vector delivery of TGF-
β1 transgene 
Single I.T. dose 35 
Mouse Asbestos Single I.T. dose 27 
Rat Paraquat Single O.G. dose 29,31  
Mouse Paraquat Single I.P. dose 30 
Mouse Human IPF Cells Single I.V. infusion 37 
This table is not an exhaustive list of all animal models of IPF, rather it is a selection intended to give the reader an insight 172 
into the wide variety of models that have been used to investigate IPF. 173 
 174 
Effect of drugs in pre-clinical models of pulmonary fibrosis 175 
A wide variety of different compounds with different mechanisms of action have shown efficacy in 176 
animal models of pulmonary fibrosis (see Table 2). However, currently only 2 compounds have been 177 
approved for the treatment of IPF in humans. In addition to the choice of animal model another 178 
variable that is introduced when investigating novel potential anti fibrotic compounds in animal 179 
models of pulmonary fibrosis is the dosing regimen used for the drug. Generally, the administration 180 
of compounds falls into the categories of either prophylactic or therapeutic administration. Dosing 181 
of compounds that are tested prophylactically commences before or on the same day that the 182 
fibrosis is first induced.  In contrast when drugs are tested therapeutically, this typically begins once 183 
the fibrosis is established (for example in the single IT bleomycin model, day 10-14 is often used as 184 
the start day for therapeutic dosing with a test compound).  185 
Compounds such as prednisolone or melatonin which are anti-inflammatory and anti-oxidant 186 
compounds respectively, and other compounds having similar mechanisms of action have shown 187 
some efficacy in pre-clinical models when dosed prophylactically [23, 30, 58, 62 ,65 ,66]. However, 188 
anti-inflammatory and anti-oxidant therapy have only shown very weak benefit, if any, in the 189 
treatment of pulmonary fibrosis in the clinic [67,68], and their use is currently not recommended in 190 
the treatment of IPF [69]. A recent phase 2 clinical trial explored the possibility of combining an anti-191 
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inflammatory and anti-oxidant compound, N-acetylcysteine, with Pirfenidone treatment. 192 
Unfortunately this study concluded that the minor treatment related change in forced vital capacity 193 
(FVC) in patients receiving this combination therapy suggested that marginal clinical benefit, but 194 
potentially increased unwanted effects compared with treating with Pirfenidone alone [70]. 195 
Another distinct class of compound that has shown promise pre-clinically are anti-coagulants [49, 71, 196 
72]. However, clinical trials with anticoagulants in patients with IPF have not yielded any positive 197 
results, with warfarin showing a negative effect on mortality [73]. Warfarin depletes vitamin K, 198 
which affects a wide range of clotting factors [74].  It has been suggested by groups such as 199 
Chambers et al [75] that a more narrowly targeted local anti-coagulant approach may still have merit 200 
in the treatment of IPF. For example, targeting of PAR 1 in a mouse single I.T. bleomycin dose model 201 
[76] and clotting factor Xa in a mouse single O.A. bleomycin dose model [72] in vivo have been 202 
shown to reduce levels of fibrosis. 203 
Other classes of compound such as certain classes of antibiotics [33, 48], angiogenesis inhibitors [29, 204 
60] and mucolytics [61] have shown similar efficacy in pre-clinical models, but this has not translated 205 
to the clinic [77-79].  206 
However, there are emerging targets that have shown promise pre-clinically that have not yet been 207 
fully investigated clinically such as inhibition of the autotaxin pathway [80, 81] and there are 208 
currently on-going clinical trials investigating the use of an autotaxin inhibitor in patients with IPF 209 
[82]. 210 
 211 
Table 2: Effect of drugs in preclinical models of IPF 
Model used Compound Timing of dose 
administration 
Mechanism of action Summary of pre-
clinical effect 
Ref 
Mouse repeat 
I.V. bleomycin 
Pirfenidone Prophylactic Broad spectrum anti-
fibrotic and anti-
inflammatory 
Reduction in lung 
hydroxyproline and 
histological fibrosis 
scores 
23 
Mouse and rat 
single I.T. 
Nintedanib Prophylactic and 
therapeutic 
Broad spectrum 
tyrosine kinase 
Reduction in 
histological fibrosis 
18 
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bleomycin, 
Mouse single 
I.T. silica 
inhibitor scores 
Mouse S.C. 
bleomycin 
osmotic mini 
pump 
Imatinib 
mesylate 
Prophylactic and 
therapeutic 
(effect only seen 
with prophylactic) 
Tyrosine kinase 
inhibitor 
Reduction in 
histological fibrosis 
scores. Decrease 
collagen content in 
lungs 
57 
Mouse repeat 
I.V. bleomycin 
Prednisolone Prophylactic Corticosteroid Reduction of pro-
inflammatory 
cytokines in early 
bleomycin 
response 
23 
Mouse S.C. 
bleomycin 
osmotic mini 
pump 
IMD-0354 Prophylactic and 
therapeutic 
IκB kinase-β inhibitor Decreases in 
histological fibrosis 
scoring, body 
weight loss and 
lung collagen 
content. Improved 
survival 
58 
Rat single I.T. 
bleomycin 
Naja naja atra 
venom 
Prophylactic Anti-inflammatory and 
free radical scavenger 
Decrease in lung 
hydroxyproline 
content. Increase 
in PO2 and SO2 in 
arterial blood 
66 
Mouse single 
I.P. paraquat 
Rapamycin Prophylactic Immunosuppressant Decrease in TGF-β1 
expression, and 
lung 
hydroxyproline 
content 
30 
Rat single I.T. 
bleomycin 
Ginkgo Biloba Prophylactic Antioxidant Decreases in 
histological fibrosis 
scoring and lung 
hydroxyproline. 
62 
Rat single I.T. 
bleomycin 
Melatonin Prophylactic Hormone, Antioxidant Decreases in 
histological fibrosis 
scoring and lung 
hydroxyproline 
65 
Mouse single 
I.T. bleomycin 
Dabigatran Prophylactic and 
therapeutic 
Direct thrombin 
inhibitor 
Decreases in 
histological fibrosis 
scoring lung 
hydroxyproline 
content and BAL 
TGF-β1 levels 
71 
Mouse single 
O.A. 
bleomycin 
ZK 807834 Prophylactic Clotting factor Xa 
inhibitor 
Decreases in lung 
collagen content 
and α-SMA 
expression 
72 
Mouse single 
I.T. bleomycin 
ONO-1301 Prophylactic Prostacyclin agonist 
with thromboxane 
synthase inhibitory 
Decreases in 
histological fibrosis 
scoring and lung 
49 
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activity hydroxyproline. 
Increase in survival 
rate 
Mouse single 
I.T. bleomycin 
Doxycycline Prophylactic Tetracycline 
(antibiotic) 
Decreases in 
histological fibrosis 
scoring and lung 
hydroxyproline 
48 
Mouse 
Radiation 
Clarithromycin Prophylactic Macrolide (antibiotic) Reduction in 
histological fibrosis 
scores,  TGF-β1 
gene expression, 
and lung collagen 
content 
33 
Rat Single I.T. 
bleomycin 
Endostatin Prophylactic and 
therapeutic 
(effect only seen 
with prophylactic) 
Angiogenesis inhibitor Decrease in 
expression of VEGF 
and TGF-β1, 
decrease in 
inflammation in 
early bleomycin 
response 
60 
Rat single O.G. 
paraquat 
Losartan Prophylactic Angiotensin II receptor 
antagonist 
Decrease in TGF-β1 
expression, and 
lung 
hydroxyproline 
content 
29 
Rat single I.T. 
bleomycin 
Erdosteine Prophylactic Mucolytic/Anti-
oxidant 
Decreases in 
histological fibrosis 
scoring 
61 
Mouse single 
I.T. bleomycin 
GWJ-A-23 Prophylactic Autotaxin inhibitor Decrease in lung 
collagen content, 
BAL collagen 
content and BAL 
TGF-β1 content 
80 
This table is not an exhaustive list of all compounds that have shown  efficacy in pre-clinical models of IPF; rather it is a 212 
selection intended to give the reader an insight into the wide variety of compounds and different mechanisms of action 213 
that have been evaluated pre-clinically. 214 
 215 
A way forward for pre-clinical models of pulmonary fibrosis? 216 
It can be seen from the above discussion that the current preclinical models are a poor predictor of 217 
clinical efficacy.  This may be due to deficiencies in the design of both pre-clinical and clinical studies, 218 
but here we focus only on improvements that could be made to the design of pre-clinical studies in 219 
IPF. 220 
The majority of the compounds tested pre-clinically for the treatment of IPF are tested in models 221 
where a single fibrotic insult is used. In humans the development of IPF is thought to be progressive 222 
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and due to repeated micro-injuries [59]. Models that use repeated smaller insults that result in a 223 
progressive development of fibrosis such described elsewhere [3-6] may provide a better model of 224 
pulmonary fibrosis. 225 
Perhaps one of the biggest issues questioning the relevance of many of the existing preclinical 226 
models of IPF to evaluate new drugs is that the majority of studies test compounds by using a 227 
prophylactic dosing regimen. It is possible that the pre-clinical compounds may be able to interfere 228 
with the mechanisms by which bleomycin or other fibrotic insults cause fibrosis, but have little effect 229 
on established fibrosis that would be present in patients with IPF who enter clinical trials.  It would 230 
seem sensible therefore to only evaluate novel drugs destined for the treatment of IPF in animal 231 
models of established fibrosis.  This should therefore reduce the number of “false positives” arising 232 
from preclinical work and clearly reduce the number of animals used in the assessment of drugs for 233 
the treatment of IPF.   234 
Another major issue is the choice of species and thus the endpoints that are most commonly 235 
examined in pre-clinical models of IPF which are almost always histological scores (commonly 236 
modified Ashcroft scoring [83, 84]), lung collagen or hydroxyproline (a major component of collagen) 237 
content, and occasionally TGF-β1 expression or levels in the lungs, or levels recovered in BAL fluid in 238 
mice or rats. Although these endpoints give valuable information about the levels of fibrosis in the 239 
lungs of animals they may not provide the whole picture and most models rarely measure any 240 
functional readouts such as lung function decline or impairment in gas exchange, changes which are 241 
the hallmark of IPF clinically, in part this is because it is difficult to measure such changes robustly in 242 
mice. Clinically repeated lung biopsies to examine histopathological changes and measure the 243 
collagen contents are limited.  However, high resolution CT imaging and functional endpoints such as 244 
forced vital capacity, forced expiratory volume in one second, diffusing capacity of the lungs for 245 
carbon monoxide or 6 minute walking distance are used to diagnose and monitor patients with 246 
pulmonary fibrosis. It has previously been shown that imaging techniques such as MRI or SPECT/CT 247 
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[52, 85, 86] can be used in animal models to assess levels of pulmonary fibrosis. These techniques, as 248 
well as being more clinically relevant, provide researchers with the opportunity to longitudinally 249 
examine the progression of pulmonary fibrosis in a single animal, rather than having to sacrifice 250 
numerous animals to examine the fibrosis. There are also systems available to measure many 251 
different clinically relevant lung function end points in animals. However, neither imaging nor lung 252 
function is commonly assessed in mice, possibly due to the large cost and time implication that can 253 
be involved when assessing these endpoints. Despite the cost and time that these techniques may 254 
take the assessment of more clinically relevant endpoints in pre-clinical models of pulmonary fibrosis 255 
may give a better indication of translation of the potential treatment from the in vivo models to the 256 
clinic. 257 
 258 
 259 
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